prikaz prve stranice dokumenta Clinical application of genotype-guided dosing of warfarin in patients with acute stroke
  Preuzmi
PDF 454.07 KB
Znanstveni rad - Izvorni znanstveni rad
Clinical application of genotype-guided dosing of warfarin in patients with acute stroke
Archives of Medical Research, 46 (2015), 4; 265-273. https://doi.org/10.1016/j.arcmed.2015.05.001
Šupe, Svjetlana; Poljaković, Zdravka; Božina, Tamara; Ljevak, Josip; Macolić Šarinić, Viola; Božina, Nada

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Šupe, S., Poljaković, Z., Božina, T., Ljevak, J., Macolić Šarinić, V. i Božina, N. (2015). Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Archives of Medical Research, 46. (4), 265-273. doi: 10.1016/j.arcmed.2015.05.001

Šupe, Svjetlana, et al. "Clinical application of genotype-guided dosing of warfarin in patients with acute stroke." Archives of Medical Research, vol. 46, br. 4, 2015, str. 265-273. https://doi.org/10.1016/j.arcmed.2015.05.001

Šupe, Svjetlana, Zdravka Poljaković, Tamara Božina, Josip Ljevak, Viola Macolić Šarinić i Nada Božina. "Clinical application of genotype-guided dosing of warfarin in patients with acute stroke." Archives of Medical Research 46, br. 4 (2015): 265-273. https://doi.org/10.1016/j.arcmed.2015.05.001

Šupe, S., et al. (2015) 'Clinical application of genotype-guided dosing of warfarin in patients with acute stroke', Archives of Medical Research, 46(4), str. 265-273. doi: 10.1016/j.arcmed.2015.05.001

Šupe S, Poljaković Z, Božina T, Ljevak J, Macolić Šarinić V, Božina N. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Archives of Medical Research [Internet]. 05.2015. [pristupljeno 26.11.2024.];46(4):265-273. doi: 10.1016/j.arcmed.2015.05.001

S. Šupe, Z. Poljaković, T. Božina, J. Ljevak, V. Macolić Šarinić i N. Božina, "Clinical application of genotype-guided dosing of warfarin in patients with acute stroke", Archives of Medical Research, vol. 46, br. 4, str. 265-273, Svibanj 2015. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:104568. [Citirano: 26.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:104568
Podaci o radu
Naslov (engleski)Clinical application of genotype-guided dosing of warfarin in patients with acute stroke
AutorSvjetlana Šupe
AutorZdravka Poljaković
AutorTamara Božina
AutorJosip Ljevak
AutorViola Macolić Šarinić
AutorNada Božina
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
BACKGROUND: Patients with certain types of stroke need urgent anticoagulation and it is extremely important for them to achieve fast and stable anticoagulant effect and receive individualized treatment during the initiation of warfarin therapy. ----- METHODS: We conducted a prospective study among 210 acute stroke patients who had an indication for anticoagulation and compared the impact of CYP2C9 and VKORC1 genotype-guided warfarin dosing (PhG) with fixed dosing (NPhG) on anticoagulation control and clinical outcome between groups. ----- RESULTS: PhG achieved target INR values earlier, i.e., on average in 4.2 (4.1-4.7, 95% CI) days compared to NPhG (5.2 days [4.7-6.4, 95% CI]) (p = 0.0009), spent a higher percentage of time in the therapeutic INR range (76.3% [74.7-78.5, 95% CI] vs. 67.1% [64.5-69.6, 95% CI] in NPhG), and spent less time overdosed (INR > 3.1) (PhG 0.4 [0.1-0.7, 95% CI], NPhG 1.7 [1.1-2.3, 95% CI] days; p >0.000). PhG reached stable maintenance dose faster (10 [9.9-10.7, 95% CI] vs. 13.9 [13.3-14.7, 95% CI] days in controls; p = 0.0049) and had a better clinical outcome in relation to neurological deficit on admission as compared to NPhG. ----- CONCLUSION: We confirmed that warfarin therapy with genotype-guided dosing instead of fixed dosing reduces the time required for stabilization and improves anticoagulant control with better clinical outcome in early stages of warfarin therapy introduction among acute stroke patients, which is essential for clinical practice.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaArchives of Medical Research
Brojčani podacivol. 46, br. 4, str. 265-273
p-ISSN0188-4409
DOIhttps://doi.org/10.1016/j.arcmed.2015.05.001
URN:NBNurn:nbn:hr:105:104568
Datum objave publikacije2015-05
URL dokumentahttps://doi.org/10.1016/j.arcmed.2015.05.001
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 08:39:13